The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia.
Richel
D J
DJ
Department of Hematology, Leiden University Medical Center.
Colly
L P
LP
Willemze
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D000077209:Decitabine; D004341:Drug Evaluation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D000077209:Decitabine; D001374:Azacitidine